CanSinoBIO's mRNA Covid-19 vaccine candidate cleared for trials in China

Chinese vaccine developer CanSino Biologics Inc (CanSinoBIO) said on Monday its potential Covid-19 vaccine using the messenger RNA (mRNA) technology has been approved by China's medical products regulator to enter clinical trials.

Unlike other major countries, China has yet to approve any foreign-made mRNA vaccines such as those produced by US-German duo Pfizer Inc and BioNTech SE.

With around 88 percent of its 1.4 billion population already vaccinated, China is...